您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > TGR5 Receptor Agonist
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TGR5 Receptor Agonist
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TGR5 Receptor Agonist图片
CAS NO:1197300-24-5
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
TGR5 Receptor Agonist (CCDC) 是一种有效的武田 G 蛋白偶联受体 5 (TGR5;GPCR19) 激动剂,在 U2-OS 细胞和黑色素细胞中显示出提高的效力,pEC50 分别为 6.8 和 7.5。
Cas No.1197300-24-5
别名CCDC
化学名3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide
Canonical SMILESCC1=C(C(N(C2=CC=C(Cl)C=C2)C)=O)C(C3=CC=CC=C3Cl)=NO1
分子式C18H14Cl2N2O2
分子量361.22
溶解度DMF: 50 mg/ml,DMSO: 50 mg/ml,DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml,Ethanol: 30 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

TGR5 Receptor Agonist is a potent and selective agonist of TGR5 G-protein receptor with a pEC50 value of 6.8 in the U2-OS cell assay [1].

TGR5 Receptor Agonist has been shown the activated potency of TGR5 receptor with pEC50 values of 6.8 and 7.5 in the U2-OS cells and melanophire cells assay, respectively. In addition, TGR5 Receptor Agonist has been found to be fully specific for the human TGR5 receptor in the U2-OS and melanophore cell lines and also selective against other 7TM receptors. Besides, TGR5 Receptor Agonist has been reported to have physicochemical properties and no measurable activity against the common cytochrome P450 (CYP450) isoforms or hERG dofetilide binding with a pIC50 value of<4.3.

References:
[1] Evans KA1, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL, Rimele TJ, Armour SL, Weaver SP, Griffin RJ, Tadepalli SM, Jeune MR, Shearer TW, Chen ZB, Chen L, Anderson DL, Becherer JD, De Los Frailes M, Colilla FJ. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem. 2009 Dec 24;52(24):7962-5.